The diagnosis of progressive supranuclear palsy: current opinions and challenges

References

• Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;(10):333–359.
   PubMedGoogle Scholar
• Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44(11):2015–2019.
   PubMed Web of Science ®Google Scholar
• Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1–9.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156–171.
   PubMedGoogle Scholar
• Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord. 2013;28(4):504–509.
   PubMed Web of Science ®Google Scholar
• Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s Syndrome and PSP-Parkinsonism. Brain. 2005;128(Pt 6):1247–1258.
   PubMed Web of Science ®Google Scholar
• Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29(14):1758–1766.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Boeve BF, Duffy JR, et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase. 2005;11(4):283–296.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Duffy JR, Strand EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006;129(Pt 6):1385–1398.
   PubMed Web of Science ®Google Scholar
• Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase. 2012;18(6):478–488.
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Josephs KA, Boeve BF, et al. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord. 2005;20(8):982–988.
   PubMed Web of Science ®Google Scholar
• Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17(6):1255–1264.
   PubMed Web of Science ®Google Scholar
• Respondek G, Hoglinger GU. The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord. 2016;22(Supplement1):S34–S36.
   PubMedGoogle Scholar
• Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord. 2003;18(9):1018–1026.
   PubMed Web of Science ®Google Scholar
• Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord. 2017;32(7):995–1005.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–864.
   PubMed Web of Science ®Google Scholar
• Arena JE, Weigand SD, Whitwell JL, et al. Progressive supranuclear palsy: progression and survival. J Neurol. 2016;263(2):380–389.
   PubMed Web of Science ®Google Scholar
• Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60(6):615–620.
   PubMed Web of Science ®Google Scholar
• Cosseddu M, Benussi A, Gazzina S, et al. Natural history and predictors of survival in progressive supranuclear palsy. J Neurol Sci. 2017;(382):105–107.
   PubMedGoogle Scholar
• Takigawa H, Kitayama M, Wada-Isoe K, et al. Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade. Brain Behav. 2016;6(12):e00557.
   PubMed Web of Science ®Google Scholar
• Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736–1743.
   PubMed Web of Science ®Google Scholar
• Caparros-Lefebvre D, Golbe LI, Deramecourt V, et al. A geographical cluster of progressive supranuclear palsy in northern France. Neurology. 2015;85(15):1293–1300.
   PubMed Web of Science ®Google Scholar
• Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(5):402–411.
   PubMed Web of Science ®Google Scholar
• Litvan I, Lees PS, Cunningham CR, et al. Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. Mov Disord. 2016;31(5):644–652.
   PubMed Web of Science ®Google Scholar
• Park HK, Ilango S, Charriez CM, et al. Lifetime exposure to estrogen and progressive supranuclear palsy: environmental and genetic PSP study. Mov Disord. 2018;33(3):468–472.
   PubMed Web of Science ®Google Scholar
• Dugger BN, Hentz JG, Adler CH, et al. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol. 2014;73(3):244–252.
   PubMed Web of Science ®Google Scholar
• Nogami A, Yamazaki M, Saito Y, et al. Early stage of progressive supranuclear palsy: a neuropathological study of 324 consecutive autopsy cases. J Nippon Med Sch. 2015;82(6):266–273.
   PubMed Web of Science ®Google Scholar
• Morris HR, Gibb G, Katzenschlager R, et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain. 2002;125(Pt 5):969–975.
   PubMedGoogle Scholar
• Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord. 2010;25(3):357–362.
   PubMed Web of Science ®Google Scholar
• Iodice V, Lipp A, Ahlskog JE, et al. Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry. 2012;83(4):453–459.
   PubMed Web of Science ®Google Scholar
• Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, et al. Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol. 2014;261(8):1575–1583.
   PubMed Web of Science ®Google Scholar
• Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord. 2007;22(15):2235–2241.
   PubMed Web of Science ®Google Scholar
• Owens E, Josephs KA, Savica R, et al. The clinical spectrum and natural history of pure akinesia with gait freezing. J Neurol. 2016;263(12):2419–2423.
   PubMed Web of Science ®Google Scholar
• Kurz C, Ebersbach G, Respondek G, et al. An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. Acta Neuropathol Commun. 2016;4(1):120.
   PubMedGoogle Scholar
• Boxer AL, Garbutt S, Seeley WW, et al. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch Neurol. 2012;69(4):509–517.
   PubMedGoogle Scholar
• Otero-Millan J, Serra A, Leigh RJ, et al. Distinctive features of saccadic intrusions and microsaccades in progressive supranuclear palsy. J Neurosci. 2011;31(12):4379–4387.
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–2477.
   PubMed Web of Science ®Google Scholar
• Forrest SL, Kril JJ, Stevens CH, et al. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain. 2018;141(2):521–534.
   PubMedGoogle Scholar
• Josephs KA, Duffy JR, Strand EA, et al. The evolution of primary progressive apraxia of speech. Brain. 2014;137(Pt 10):2783–2795.
   PubMedGoogle Scholar
• Spinelli EG, Mandelli ML, Miller ZA, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. 2017;81(3):430–443.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496–503.
   PubMed Web of Science ®Google Scholar
• Ling H, de Silva R, Massey LA, et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol. 2014;40(2):149–163.
   PubMed Web of Science ®Google Scholar
• Ling H, O’Sullivan SS, Holton JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133(Pt 7):2045–2057.
   PubMedGoogle Scholar
• Koga S, Josephs KA, Ogaki K, et al. Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C. Mov Disord. 2016;31(5):653–662.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Katsuse O, Beccano-Kelly DA, et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol. 2006;65(4):396–405.
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Bigio EH, Budka H, et al. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol. 2013;126(4):537–544.
   PubMed Web of Science ®Google Scholar
• Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23(4):394–400.
   PubMed Web of Science ®Google Scholar
• Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246(Suppl 2):II6–15.
   PubMedGoogle Scholar
• Kneynsberg A, Combs B, Christensen K, et al. Axonal degeneration in tauopathies: disease relevance and underlying mechanisms. Front Neurosci. 2017;(11):1–14.
   PubMed Web of Science ®Google Scholar
• Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. 1996;55(1):97–105.
   PubMed Web of Science ®Google Scholar
• Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s Syndrome. Brain. 2007;130(Pt 6):1566–1576.
   PubMedGoogle Scholar
• Seo SW, Thibodeau MP, Perry DC, et al. Early vs. late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology. 2018;90(12):e1047–e1056.
   PubMedGoogle Scholar
• Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol. 2008;21(6):688–692.
   PubMed Web of Science ®Google Scholar
• Evidente VG, Adler CH, Sabbagh MN, et al. Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? Parkinsonism Relat Disord. 2011;17(5):365–371.
   PubMed Web of Science ®Google Scholar
• Dugger BN, Adler CH, Shill HA, et al. Concomitant pathologies among a spectrum of Parkinsonian disorders. Parkinsonism Relat Disord. 2014;20(5):525–529.
   PubMed Web of Science ®Google Scholar
• Koga S, Sanchez-Contreras M, Josephs KA, et al. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov Disord. 2017;32(2):246–255.
   PubMed Web of Science ®Google Scholar
• Weingarten MD, Lockwood AH, Hwo SY, et al. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975;72(5):1858–1862.
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Potier MC, et al. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8(2):393–399.
   PubMed Web of Science ®Google Scholar
• Bodea LG, Eckert A, Ittner LM, et al. Tau physiology and pathomechanisms in frontotemporal lobar degeneration. J Neurochem. 2016;138(Suppl 1):71–94.
   PubMedGoogle Scholar
• Myers AJ, Pittman AM, Zhao AS, et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2007;25(3):561–570.
   PubMed Web of Science ®Google Scholar
• Gibb GM, de Silva R, Revesz T, et al. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Brain Res Mol Brain Res. 2004;121(1–2):95–101.
   PubMedGoogle Scholar
• Trabzuni D, Wray S, Vandrovcova J, et al. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet. 2012;21(18):4094–4103.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699–705.
   PubMed Web of Science ®Google Scholar
• Gu J, Chen F, Iqbal K, et al. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: implications for the pathogenesis of tauopathies. J Biol Chem. 2017;292(25):10600–10612.
   PubMed Web of Science ®Google Scholar
• Huin V, Buee L, Behal H, et al. Alternative promoter usage generates novel shorter MAPT mRNA transcripts in Alzheimer’s disease and progressive supranuclear palsy brains. Sci Rep. 2017;7(1):12589.
   PubMedGoogle Scholar
• Morris M, Knudsen GM, Maeda S, et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci. 2015;18(8):1183–1189.
   PubMed Web of Science ®Google Scholar
• Hanger DP, Noble W. Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis. 2011;352805:2011.
   Google Scholar
• Zhao Y, Tseng IC, Heyser CJ, et al. Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. Neuron. 2015;87(5):963–975.
   PubMed Web of Science ®Google Scholar
• Zhang CC, Xing A, Tan MS, et al. The role of MAPT in neurodegenerative diseases: genetics, mechanisms and therapy. Mol Neurobiol. 2016;53(7):4893–4904.
   PubMed Web of Science ®Google Scholar
• DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481–0430.
   PubMed Web of Science ®Google Scholar
• Schoch KM, DeVos SL, Miller RL, et al. Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron. 2016;90(5):941–947.
   PubMed Web of Science ®Google Scholar
• Clavaguera F, Akatsu H, Fraser G, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013;110(23):9535–9540.
   PubMed Web of Science ®Google Scholar
• Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010;142(3):387–397.
   PubMed Web of Science ®Google Scholar
• Sanders DW, Kaufman SK, DeVos SL, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271–1288.
   PubMed Web of Science ®Google Scholar
• Allen M, Burgess JD, Ballard T, et al. Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathol. 2016;132(2):197–211.
   PubMed Web of Science ®Google Scholar
• Coppola G, Chinnathambi S, Lee JJ, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer’s diseases. Hum Mol Genet. 2012;21(15):3500–3512.
   PubMed Web of Science ®Google Scholar
• Fujioka S, Sanchez Contreras MY, Strongosky AJ, et al. Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. Parkinsonism Relat Disord. 2015;21(2):101–105.
   PubMed Web of Science ®Google Scholar
• Ros R, Thobois S, Streichenberger N, et al. A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. Arch Neurol. 2005;62(9):1444–1450.
   PubMedGoogle Scholar
• Gustavsson EK, Trinh J, Guella I, et al. DCTN1 p.K56R in progressive supranuclear palsy. Parkinsonism Relat Disord. 2016;28(C):56–61.
   PubMedGoogle Scholar
• Wilke C, Baets J, De Bleecker JL, et al. Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. Neurobiol Aging. 2018;62:244 e249–244 e213.
   Web of Science ®Google Scholar
• Wilke C, Pomper JK, Biskup S, et al. Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. J Neurol. 2016;263(3):558–574.
   PubMed Web of Science ®Google Scholar
• Yokoyama JS, Karch CM, Fan CC, et al. Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol. 2017;133(5):825–837.
   PubMed Web of Science ®Google Scholar
• Agosta F, Caso F, Jecmenica-Lukic M, et al. Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study. J Neurol Neurosurg Psychiatry. 2018;89:696–701. jnnp-2017-317443-317447.
   PubMedGoogle Scholar
• Tsuboi Y, Slowinski J, Josephs KA, et al. Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology. 2003;60(11):1766–1769.
   PubMed Web of Science ®Google Scholar
• Quattrone A, Morelli M, Williams DR, et al. MR Parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-Parkinsonism. Neurology. 2016;87(12):1266–1273.
   PubMed Web of Science ®Google Scholar
• Mangesius S, Hussl A, Krismer F, et al. MR planimetry in neurodegenerative Parkinsonism yields high diagnostic accuracy for PSP. Parkinsonism Relat Disord. 2018;(46):47–55.
   PubMedGoogle Scholar
• Owens E, Krecke K, Ahlskog JE, et al. Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy. Parkinsonism Relat Disord. 2016;28(C):107–111.
   PubMedGoogle Scholar
• Whitwell JL, Jack CR Jr., Parisi JE, et al. Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. Eur J Neurol. 2013;20(10):1417–1422.
   PubMed Web of Science ®Google Scholar
• Mueller C, Hussl A, Krismer F, et al. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative Parkinsonism. Parkinsonism Relat Disord. 2018. In Press. doi: 10.1016/j.parkreldis.2018.04.005
   Google Scholar
• Josephs KA, Whitwell JL, Eggers SD, et al. Gray matter correlates of behavioral severity in progressive supranuclear palsy. Mov Disord. 2011;26(3):493–498.
   PubMed Web of Science ®Google Scholar
• Dutt S, Binney RJ, Heuer HW, et al. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016;87(19):2016–2025.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Schope J, Stamelou M, et al. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: a new combined score for clinical trials. Mov Disord. 2017;32(6):842–852.
   PubMed Web of Science ®Google Scholar
• Ito S, Makino T, Shirai W, et al. Diffusion tensor analysis of corpus callosum in progressive supranuclear palsy. Neuroradiology. 2008;50(11):981–985.
   PubMed Web of Science ®Google Scholar
• Agosta F, Galantucci S, Svetel M, et al. Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy. J Neurol. 2014;261(5):913–924.
   PubMed Web of Science ®Google Scholar
• Whitwell JL, Master AV, Avula R, et al. Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol. 2011;68(6):753–760.
   PubMedGoogle Scholar
• Whitwell JL, Avula R, Master A, et al. Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord. 2011;17(8):599–605.
   PubMed Web of Science ®Google Scholar
• Worker A, Blain C, Jarosz J, et al. Diffusion tensor imaging of Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study. PLoS ONE. 2014;9(11):e112638.
   PubMed Web of Science ®Google Scholar
• Whitwell JL, Schwarz CG, Reid RI, et al. Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord. 2014;20(5):493–498.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Walter R, Ng P, et al. Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: a longitudinal diffusion tensor imaging study. PLoS ONE. 2016;11(6):e0157218.
   PubMed Web of Science ®Google Scholar
• Agosta F, Pievani M, Svetel M, et al. Diffusion tensor MRI contributes to differentiate Richardson’s syndrome from PSP-Parkinsonism. Neurobiol Aging. 2012;33(12):2817–2826.
   PubMed Web of Science ®Google Scholar
• Coon EA, Whitwell JL, Jack CR Jr., et al. Primary lateral sclerosis as progressive supranuclear palsy: diagnosis by diffusion tensor imaging. Mov Disord. 2012;27(7):903–906.
   PubMed Web of Science ®Google Scholar
• Botha H, Whitwell JL, Madhaven A, et al. The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism Relat Disord. 2014;20(2):180–185.
   PubMed Web of Science ®Google Scholar
• Smith R, Scholl M, Honer M, et al. Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol. 2017;133(1):149–151.
   PubMed Web of Science ®Google Scholar
• Zalewski N, Botha H, Whitwell JL, et al. FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol. 2014;261(4):710–716.
   PubMed Web of Science ®Google Scholar
• Teune LK, Renken RJ, Mudali D, et al. Validation of Parkinsonian disease-related metabolic brain patterns. Mov Disord. 2013;28(4):547–551.
   PubMed Web of Science ®Google Scholar
• Badoud S, Van De Ville D, Nicastro N, et al. Discriminating among degenerative Parkinsonisms using advanced (123)I-ioflupane SPECT analyses. Neuroimage Clin. 2016;12:234–240.
   PubMed Web of Science ®Google Scholar
• Antonini A, Benti R, De Notaris R, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24(3):149–150.
   PubMed Web of Science ®Google Scholar
• Van Laere K, Casteels C, De Ceuninck L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006;47(3):384–392.
   PubMed Web of Science ®Google Scholar
• Im JH, Chung SJ, Kim JS, et al. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson’s disease: analysis with [(123)I]IPT single photon emission computed tomography. J Neurol Sci. 2006;244(1–2):103–109.
   PubMed Web of Science ®Google Scholar
• Oh M, Kim JS, Kim JY, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012;53(3):399–406.
   PubMed Web of Science ®Google Scholar
• Fasano A, Baldari S, Di Giuda D, et al. Nigro-striatal involvement in primary progressive freezing gait: insights into a heterogeneous pathogenesis. Parkinsonism Relat Disord. 2012;18(5):578–584.
   PubMed Web of Science ®Google Scholar
• Lin WY, Lin KJ, Weng YH, et al. Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy. Nucl Med Commun. 2010;31(11):974–980.
   PubMed Web of Science ®Google Scholar
• Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013;9(6):666–676.
   PubMed Web of Science ®Google Scholar
• Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787–800.
   PubMed Web of Science ®Google Scholar
• Lemoine L, Gillberg PG, Svedberg M, et al. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017;9(1):96.
   PubMedGoogle Scholar
• Ono M, Sahara N, Kumata K, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain. 2017;140(3):764–780.
   PubMedGoogle Scholar
• Whitwell JL, Lowe VJ, Tosakulwong N, et al. [(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017;32(1):124–133.
   PubMed Web of Science ®Google Scholar
• Passamonti L, Vazquez Rodriguez P, Hong YT, et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2017;140(3):781–791.
   PubMedGoogle Scholar
• Schonhaut DR, McMillan CT, Spina S, et al. (18) F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017;82(4):622–634.
   PubMed Web of Science ®Google Scholar
• Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord. 2017;32(1):108–114.
   PubMed Web of Science ®Google Scholar
• Cho H, Choi JY, Hwang MS, et al. Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2017;32(1):134–140.
   PubMed Web of Science ®Google Scholar
• Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58.
   PubMedGoogle Scholar
• Sander K, Lashley T, Gami P, et al. Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12(11):1116–1124.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lyoo CH, Ahn SJ, et al. Brain regional iron contents in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;(45):28–32.
   PubMedGoogle Scholar
• Coakeley S, Cho SS, Koshimori Y, et al. [(18)F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. Brain Struct Funct. 2018;223(2):589–595.
   PubMed Web of Science ®Google Scholar
• Hostetler ED, Walji AM, Zeng Z, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599–1606.
   PubMed Web of Science ®Google Scholar
• Declercq L, Rombouts F, Koole M, et al. Preclinical evaluation of (18)F-JNJ64349311, a novel PET tracer for tau imaging. J Nucl Med. 2017;58(6):975–981.
   PubMed Web of Science ®Google Scholar
• Whitwell JL, Ahlskog JE, Tosakulwong N, et al. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer’s disease in progressive supranuclear palsy. Parkinsonism Relat Disord. 2018;48:3–9.
   PubMed Web of Science ®Google Scholar
• Gardner RC, Boxer AL, Trujillo A, et al. Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol. 2013;73(5):603–616.
   PubMed Web of Science ®Google Scholar
• Rosskopf J, Gorges M, Muller HP, et al. Intrinsic functional connectivity alterations in progressive supranuclear palsy: differential effects in frontal cortex, motor, and midbrain networks. Mov Disord. 2017;32(7):1006–1015.
   PubMed Web of Science ®Google Scholar
• Jones DT, Graff-Radford J, Lowe VJ, et al. Tau, amyloid, and cascading network failure across the Alzheimer’s disease spectrum. Cortex. 2017;(97):143–159.
   PubMedGoogle Scholar
• Jones DT, Knopman DS, Gunter JL, et al. Cascading network failure across the Alzheimer’s disease spectrum. Brain. 2016;139(Pt 2):547–562.
   PubMedGoogle Scholar
• Rittman T, Rubinov M, Vertes PE, et al. Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. Neurobiol Aging. 2016;48(C):153–160.
   PubMedGoogle Scholar
• Noguchi M, Yoshita M, Matsumoto Y, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2005;237(1–2):61–65.
   PubMed Web of Science ®Google Scholar
• Rojas JC, Bang J, Lobach IV, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018;90(4):e273–e281.
   PubMed Web of Science ®Google Scholar
• Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216–225.
   PubMed Web of Science ®Google Scholar
• Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1):116–126.
   PubMed Web of Science ®Google Scholar
• Lamb R, Rohrer JD, Lees AJ, et al. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol. 2016;18(9):42.
   PubMed Web of Science ®Google Scholar
• Stamelou M, Bhatia KP. Atypical Parkinsonism: diagnosis and treatment. Neurol Clin. 2015;33(1):39–56.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Jitkritsadakul O, Boonrod N, et al. Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy. Clin Neurol Neurosurg. 2014;(116):1–3.
   PubMedGoogle Scholar
• Cardoso F. Botulinum toxin in Parkinsonism: the when, how, and which for botulinum toxin injections. Toxicon. 2018;(147):107–110.
   PubMedGoogle Scholar
• Gomez-Caravaca MT, Caceres-Redondo MT, Huertas-Fernandez I, et al. The use of botulinum toxin in the treatment of sialorrhea in Parkinsonian disorders. Neurol Sci. 2015;36(2):275–279.
   PubMed Web of Science ®Google Scholar
• Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018;33(3):372–390.
   PubMed Web of Science ®Google Scholar
• Clerici I, Ferrazzoli D, Maestri R, et al. Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments. PLoS ONE. 2017;12(2):e0170927.
   PubMed Web of Science ®Google Scholar
• Sale P, Castiglioni D, De Pandis MF, et al. The Lee Silverman Voice Treatment (LSVT(R)) speech therapy in progressive supranuclear palsy. Eur J Phys Rehabil Med. 2015;51(5):569–574.
   PubMed Web of Science ®Google Scholar
• Wiblin L, Lee M, Burn D. Palliative care and its emerging role in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;34(7–14):7–14.
   PubMedGoogle Scholar
• Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–478.
   PubMed Web of Science ®Google Scholar
• Hoglinger GU, Huppertz HJ, Wagenpfeil S, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord. 2014;29(4):479–487.
   PubMed Web of Science ®Google Scholar
• Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676–685.
   PubMed Web of Science ®Google Scholar
• Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23(7):942–949.
   PubMed Web of Science ®Google Scholar
• Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e266.
   PubMed Web of Science ®Google Scholar
• Irwin DJ, Cohen TJ, Grossman M, et al. Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am J Pathol. 2013;183(2):344–351.
   PubMed Web of Science ®Google Scholar
• Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18(11):1584–1593.
   PubMed Web of Science ®Google Scholar
• Yuzwa SA, Shan X, Macauley MS, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012;8(4):393–399.
   PubMed Web of Science ®Google Scholar
• Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer’s disease. Trends Mol Med. 2015;21(6):394–402.
   PubMed Web of Science ®Google Scholar
• Yanamandra K, Jiang H, Mahan TE, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2(3):278–288.
   PubMed Web of Science ®Google Scholar
• Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–414.
   PubMed Web of Science ®Google Scholar
• West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alzheimers Dis. 2017;4(4):236–241.
   PubMed Web of Science ®Google Scholar
• Ali F, Whitwell JL, Martin PR, et al. [(18)F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation. J Neurol. 2018;265:1079–1088.
   PubMed Web of Science ®Google Scholar